ADXS

Ayala Pharmaceuticals, Inc.

A maker of targeted cancer drugs, Ayala Pharmaceuticals develops small-molecule therapies for rare and aggressive tumors driven by the Notch signaling pathway, with its lead candidate AL102 studied for desmoid tumors. The company traces its roots to Israeli biotech work and, in early 2023, merged with the U.S. immunotherapy firm Advaxis, whose unusual platform used a weakened form of the foodborne bacteria Listeria to train the immune system to attack cancer cells.

No proxy statement recorded.